Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 694.94

+1.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2762)	10/31/2019 12:13:37 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

Sanofi 3Q results ( finance.yahoo.com continue to demonstrate mediocre (actually disturbing mediocre) marketing and sale performance on the REGN collaborative products, outside US. <.. so ex-US Dupi sale is wild card.> No, it is not wild card. It is DISASTROUS card! Dupi 3Q US sale are $505M, which is bit light of the projected $520-525 M, based on TRx/NRx/NBRx data. It may be due to co-pay donuts hole, some WS-destocking, or who know what? My guess is that after 6 months therapy pts are scaling down on injection frequency (from 2w to 4/6-weeks interval). Will see how will TRx/NRx hold in 4Q? At least (for now), Eylea continue with double digit annual growth.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next